A genetics-led approach defines the drug target landscape of 30 immune-related traits
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide associat...
Asıl Yazarlar: | Fang, H, De Wolf, H, Knezevic, B, Burnham, K, Osgood, J, Sanniti, A, Lledó Lara, A, Kasela, S, De Cesco, S, Wegner, J, Handunnetthi, L, McCann, F, Chen, L, Sekine, T, Brennan, P, Marsden, B, Damerell, D, O’Callaghan, C, Bountra, C, Bowness, P, Sundström, Y, Milani, L, Berg, L, Göhlmann, H, Peeters, P, Fairfax, B, Sundström, M, Knight, J |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Springer Nature
2019
|
Benzer Materyaller
-
Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease
Yazar:: Handunnetthi, L, ve diğerleri
Baskı/Yayın Bilgisi: (2021) -
High-throughput structural characterisation of therapeutic protein targets.
Yazar:: Marsden, B, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
High-throughput structural characterisation of therapeutic protein targets
Yazar:: Marsden, B, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Insights for the development of specific kinase inhibitors by targeted structural genomics.
Yazar:: Fedorov, O, ve diğerleri
Baskı/Yayın Bilgisi: (2007) -
Science Forum: Donated chemical probes for open science
Yazar:: Müller, S, ve diğerleri
Baskı/Yayın Bilgisi: (2018)